Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells by Hampson, Peter et al.
Oncoscience529www.impactjournals.com/oncoscience
www.impactjournals.com/oncoscience Oncoscience 2014, Vol.1, No.8
Up-regulation of anti-apoptotic genes confers resistance to the 
novel anti-leukaemic compound PEP005 in primary AML cells
Peter Hampson1,*, Keqing Wang2, Elisabeth Ersvær3, Emmet McCormack3, Julia 
Schüler4, Heinz-Herbert Fiebig4, Bjørn Tore Gjertsen3, Øystein Bruserud3, and 
Janet M. Lord1
1 School of Immunity and Infection, University of Birmingham, Birmingham, B15 2TT, UK
2 Department of Biosciences, University of Aston, Birmingham, B4 7ET
3 Institute of Medicine, University of Bergen, Bergen, NO-5020, Norway
4 Oncotest GmbH, 79801 Freiburg, Germany
Correspondence to: Peter Hampson, email: p.hampson@bham.ac.uk
Keywords: AML, PEP005, PKC, anti-apoptotic, xenograft model
Received: June 24, 2014 Accepted: August 2, 2014 Published: August 6, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
We showed previously that PEP005 induced apoptosis in leukaemic 
cell lines and blasts from patients with acute myeloid leukaemia (AML). 
Here we assess the anti-leukeamic effects of PEP005 in vivo and determine 
the mechanism of resistance of PEP005 non-responsive cells. We used 2 
human xenograft mouse models of AML to assess the anti-leukaemic effects 
of PEP005 in vivo. Expression microarray analysis of primary AML blasts 
following treatment with PEP005 was used to determine patterns of gene 
expression that conferred resistance. PEP005 significantly reduced tumour 
burden in two human leukaemia mouse xenograft models. We also assessed 
responsiveness of 33 AML samples to PEP005, with 78% of the samples 
entering apoptosis at 100nM. Resistance to PEP005 was not restricted to a 
particular AML subtype. Expression microarray analysis of resistant samples 
following treatment with PEP005 revealed a significant up regulation of 
the anti-apoptotic genes Bcl-2A1, Mcl-1, and PHLDA1 which was verified 
using RT-PCR. We conclude that PEP005 shows broad efficacy against AML 
subtypes and that up regulation of anti-apoptotic genes underlies resistance 
to this agent and could be used to screen for patients unlikely to benefit from 
a therapeutic regime involving PEP005.
INTRODUCTION
The incidence of Acute Myeloid Leukaemia (AML) 
increases with age, with a majority of cases occurring 
in people over 65 [1]. Whilst 40%-65% of patients ≥60 
will achieve remission, around 85% will relapse within 
2-3 years [2]. This poorer prognosis is attributable in 
part to the fact that these patients are less responsive to 
myelosuppressive chemotherapy and are less able to 
tolerate therapy [3]. Overcoming these problems requires 
the development of adjunctive therapies that improve 
tumour responses while not exacerbating the systemic 
toxicities of established chemotherapeutics.
Extracts from the plant Euphorbia peplus 
(E. peplus) are active against a number of tumour cell lines 
in vitro, including strains of malignant melanoma resistant 
to conventional chemotherapeutic agents [4]. The active 
ingredient from this plant has been identified as ingenol 
3-angelate (PEP005). Topical application of PEP005 
was able to cure sub-cutaneous tumours established in 
C57BL/6 and Foxn1nu mice [5] and the compound has 
successfully completed phase IIb trials for non-melanoma 
skin cancer and solar actinic keratosis [6;7] and came to 
market for actinic keratoses in 2012. 
Our data have demonstrated that PEP005 induces 
apoptosis in several leukaemic cell lines [8] and can cause 
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the proliferation of T cells isolated from the peripheral 
blood of AML patients following intensive chemotherapy 
[9]. This is important as it has been demonstrated that 
AML patients who display early lymphoid reconstitution 
after conventional intensive chemotherapy have a reduced 
risk of later relapse [10;11]. Furthermore, PEP005 
enhances anti-CD3 and anti-CD28-induced cytokine 
release by these cells [12]. AML is classified into subtypes 
M0 to M6. As the different AML subtypes have varying 
pathogenic mechanisms they are treated with distinct 
therapeutic regimes. Although our previous publication 
showed that primary AML cells were responsive to 
PEP005 [13], we did not consider AML subtypes or the 
broad efficacy of this agent.
In order to determine which AML patients would 
benefit from PEP005 we have investigated the effects 
of PEP005 on primary AML cells isolated from patients 
diagnosed with the different subtypes of AML. In addition, 
we have investigated the effects of PEP005 in two human 
xenograft mouse models of AML to determine whether the 
agent is effective in vivo.
RESULTS
PEP005 has anti-leukaemic effects in primary 
AML blasts 
We investigated the effects of PEP005 on primary 
blasts isolated from 33 patients covering the different 
AML subtypes. Patient demographics, cell surface marker 
expression, Flt-3 mutation status and NMP1 mutation 
status of the samples tested are listed in Supplementary 
Table 1. PEP005 caused a dose-dependent reduction in 
viable cell numbers in the majority (78%) of the patient 
samples tested, and a significant reduction in cell viability 
occurred at doses as low as 10 nM, with maximal effects 
seen at 100 nM (Figure 1A). These data show that PEP005 
can induce apoptosis in the majority of primary blasts 
isolated from patients with AML. 
In order to measure the effects of PEP005 treatment 
on the proliferation of primary AML blasts, isolated 
cells were cultured in the presence of SCF, Flt-3 ligand, 
and GM-CSF, along with various concentrations of 
PEP005, and proliferation assessed with a 3H-thymidine 
incorporation assay. PEP005 inhibited the proliferation 
of AML blasts in a dose-dependent manner (Figure 1B). 
Inhibition was seen at doses as low as 2 nM, with 
optimal effects observed at 100 nM and inhibition of cell 
proliferation by PEP005 was seen in all primary AML 
samples.
PEP005 inhibits tumour growth in human AML 
xenograft mouse models in vivo
To evaluate the ability of PEP005 to inhibit the 
growth of human AML cells in vivo, we used two distinct 
human AML xenograft mouse models: a subcutaneous 
xenograft model and a systemic xenograft model. In the 
U937 subcutaneous model, tumour size was measured 
every 3 days after the start of PEP005 treatment. We found 
that PEP005 induced significant tumour growth inhibition 
when applied at 40 mg/kg/d. The most impressive tumour 
growth suppression was induced three weeks after start of 
treatment (Figure 2A and 2B), with the relative increase in 
tumour volume in the PEP005 treated group reduced from 
1929% to 763.7%.
Although subcutaneous xenograft models of 
leukaemia and lymphomas have their advantages, the 
major limitation of this model is reproducible growth 
only as localised myelosarcomas with little evidence 
of engraftment in clinically more relevant organ sites 
[16]. We therefore employed another xenograft model, 
using NOD/SCID mice as recipients. These mice were 
intravenously transplanted with GFP expressing NB4 cells, 
this cell line being chosen as we had previously shown it 
had good sensitivity to PEP005 [13]. Using this model, 
we were able to determine the degree of engraftment of 
leukaemic cells in different tissues by analysing GFP+ cell 
populations. In Table 1, NB4 cell engraftments in NOD/
SCID mice in different tissues are detailed, showing that 
a significant effect of PEP005 was seen upon the numbers 
of GFP-NB4 leukaemic cells infiltrating the superficial 
cervical lymph nodes. In subsequent experiments, NOD/
SCID/β2mnull mice were used as recipients as these mice 
displayed improved engraftment of leukaemic cells. Whole 
body imaging indicated that engraftment had occurred 
in the bone marrow (Figure 2C) and also extensively 
in other organs including the inguinal lymph nodes and 
ovaries (Figure 2D). Engraftment was visibly reduced at 
day 14 and day 20 after inoculation in the PEP005 treated 
animals (Figure 2C and 2D) and there was a significant 
decrease in GFP-NB4 cell infiltration into the abdominal 
lymph nodes at time of sacrifice (Figure 2E). These results 
show a striking anti-leukaemic activity of PEP005 in this 
aggressive murine model of AML. Despite this, PEP005 
treatment did not significantly increase the survival of the 
mice (Figure 2F), though this could have been due to low 
sample size. 
Figure 1: PEP005 has anti-leukaemic effects in vitro. 
Primary AML blasts were isolated from the peripheral blood of 
patients diagnosed with AML. A. Isolated cells were cultured 
in the absence or presence of the indicated concentrations 
of PEP005 for 3 days. Cell viability was measured using 
annexin-V/PI staining. Annexin-V negative and PI negative 
cells were taken as the viable cell population. B. Isolated cells 
were cultured in medium containing SCF, GM-CSF and Flt-3 
ligand, in the presence or absence of the indicated concentrations 
of PEP005. 7 days later, proliferation was measured using 
3H-thymidine incorporation and data are expressed as counts per 
minute (CPM). The horizontal bar indicates the mean value. ** 
indicates p<0.01, *** indicates p<0.001 
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AML patient samples can be grouped according 
to their response to PEP005
Seven of the patient samples tested (21%) had no 
apoptotic response to PEP005 and were deemed to be non-
responders (Figure 3A). 5 of the patient samples (15%) 
responded to PEP005 only at the relatively high dose of 
100 nM and were termed low responders (Figure 3B). 
The majority of patient samples (21 = 64%) responded 
to PEP005 at 10 nM and were termed high-responders 
(Figure 3C). Thus we investigated which cellular factors 
determined responsiveness of these patient samples 
to PEP005. Responsiveness was not restricted to any 
particular AML subtype and Flt-3 and NMP1 mutation 
status and karyotype did not impact upon sensitivity to 
PEP005 (Supplementary Table 1).
The resistance of AML blasts to PEP005 treatment 
does not relate to PKC-δ expression or activation
We have previously shown in leukaemic cell 
lines, that responsiveness to PEP005 was dependent 
on the expression and activation of PKC-δ [13]. We 
were therefore interested to see whether there was any 
correlation between PKC-δ expression and PEP005 
responsiveness in primary AML blasts. Figure 3D shows 
an example of the results obtained for five of the patient 
samples tested (3 PEP005 responsive and 2 PEP005 non-
responsive), showing that all of these patient samples 
expressed high levels of PKC-δ. Densitometric analysis on 
28 patient samples (20 PEP005 responsive and 8 PEP005 
non-responsive), measuring PKC-δ expression as a ratio to 
the expression of β-actin revealed no significant difference 
in PKC-δ expression between these samples (Figure 3E). 
PKC-δ activation was measured by detecting the 
phosphorylated active form of this PKC isoenzyme. 
Leukaemic PBMCs were treated for 30 minutes with 
10 nM PEP005. Phosphorylation of PKC-δ was then 
measured by western blotting using an antibody specific 
for PKC-δ phosphorylated at threonine 505 (Thr505), with 
expression of total PKC-δ used as a loading control. Figure 
3D shows an example of the analysis carried out for five 
of the patient samples tested. Phosphorylation of PKC-δ 
was detected in both PEP005 responsive and PEP005 non-
responsive patient samples. Densitometric analysis was 
performed on 28 patient samples (20 PEP005 responsive 
and 8 PEP005 non-responsive), measuring PKC-δ 
activation as a ratio of phosphorylated PKC-δ to the 
expression of total PKC-δ. Figures 3F-G show there was 
a significant activation of PKC-δ in response to PEP005 
treatment in both PEP005 responsive and non-responsive 
primary AML samples. Therefore PKC-δ expression and 
activation following PEP005 treatment cannot differentiate 
between responsive and non-responsive patient samples.
Gene expression in response to PEP005 treatment
To try and determine patterns of gene expression 
that can differentiate responsive and non-responsive cells 
and identify the molecular basis of resistance to PEP005, 
we carried out whole genome expression microarray 
analysis in primary AML samples. 6 PEP005 responsive 
and 6 non-responsive primary AML samples were treated 
with either vehicle alone or 10 nM PEP005 for 6 hours. 
Samples were restricted to the AML 1 subtype to minimise 
variation. Cells were prepared for gene expression analysis 
using the Operon 37k whole genome array. Following 
normalisation, significance analysis of microarray (SAM) 
revealed no significant differences in gene expression 
between untreated PEP005-responsive and non-responsive 
samples. Furthermore, no differences in gene expression 
were found in the PEP005-responsive samples following 
PEP005 treatment. In contrast, when comparing PEP005 
non-responsive cells, SAM analysis identified in total 134 
genes (5% error) which showed a significant change in 
expression following PEP005 treatment. Using principle 
component analysis (PCA) and hierarchical cluster 
analysis (HCA), we were able to cluster separately the 
untreated samples from the PEP005-treated samples based 
on a mean expression level difference of 2.0 (Figure 4A). 
We then went on to use Predictive Analysis of Microarray 
(PAM) to identify alterations in which genes best predicted 
whether a sample was PEP005-treated or untreated. This 
resulted in a list of 25 genes which were ranked according 
to p-value from a paired T-Test (Table 2). 3 of the most 
predictive genes were all anti-apoptotic genes. As shown 
in Table 2, PHLDA-1, Bcl-2A1 and Mcl-1 were all 
Table 1: Tissues removed from control or PEP005 treated mice after inoculation and engraftment with GFP-
NB4 human leukaemia cells were enumerated for GFP positive (+ve) cells by flow cytometry. Data are total 
cells (x 106) per tissue and are mean ± SD for 6 mice per group.
GFP-NB4 Infiltration (total cells x106 per tissue)
Treatment Mice Liver Spleen Bone Marrow
SC Lymph 
Nodes Brain Blood
Control 6 1.4 ± 0.75 2.0 ± 0.2 1.2 ± 0.41 20.2 ± 7.24 3.3 ± 1.45 1.5 ± 0.41
PEP005 
(50 µg/kg/d) 6 0.5 ± 0.29 2.4 ± 1.01 0.9 ± 0.46
1.34 ± 3.68
p<0.01 4.7 ± 2 1.1 ± 0.46
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Figure 2: The effect of PEP005 in two human xenograft mouse models of AML. U937 cells were injected subcutaneously into 
nude mice (A and B). Once cells had formed palpable tumours mice were randomized into four groups (8 mice per group) and different 
doses of PEP005 treatment were initiated. PEP005 was administered to mice by intravenous injection 3 times a week for 2 weeks. A. 
Tumour volumes were measured twice a week from day 1, and relative tumour volumes were calculated by (tumour size at day x/tumour 
size at day 0) x 100. Each point represents the median value of relative tumour volumes. B. Data are shown for individual animals at day 
21. The horizontal line represents the median value. * indicates p<0.05. (C-F) GFP expressing NB4 cells were intravenously transplanted 
in to NOD/SCID/β2mnull mice. After 2 weeks inoculation, mice were divided into two groups (6 mice per group). Vehicle control or 50 
mg/kg of PEP005 was administered to mice by intravenous injection daily for 5 days. Recipient mice were monitored and sacrificed when 
moribund, as defined by weight loss, lethargy and/or paralysis. Images showing GFP-NB4 cell engraftment in the bone marrow (C) and 
lymph nodes (D) following vehicle or PEP005 treatment. Prior to imaging, anaesthetised mice were depilated and moved to the heated 
translational stage of the eXpore Optix™. Animals were subsequently maintained under gas anaesthesia during scanning. GFP fluorescence 
images were generated using Optiview™ software. E. Inguinal lymph nodes were collected after mice were sacrificed and GFP positive 
(GFP+) cells were enumerated by flow cytometry. Data were analyzed by Flowjo software. *** indicates p<0.001 using two-way ANOVA. 
F. Survival curves in response to either vehicle (black) or PEP005 (red) treatment. 
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significantly up-regulated in response to PEP005 treatment 
in the non-responsive samples.
Validation of microarray data using RT-PCR
To validate the results obtained by microarray 
analysis, we measured gene expression of Bcl-2Al, Mcl-1 
and PHLDA-1 relative to the housekeeping gene L27 using 
qPCR. A significant up-regulation in response to PEP005 
treatment was seen for Bcl-2A1, Mcl-1 and PHLDA1 and 
was observed only in the resistant samples (Figure 4B), 
confirming the whole genome microarray data. 
DISCUSSION
We have previously shown that the novel small 
molecule PEP005 has potent anti-leukaemic effects, 
inducing apoptosis at nanomolar concentrations in 
leukaemic cell lines [13]. Here, we report that PEP005 also 
has potent anti-leukaemic effects against leukaemic cells 
isolated from patients in all AML classifications, inhibiting 
proliferation and inducing apoptosis at doses as low as 10 
nM. We also conducted pre-clinical studies using PEP005 
as a potential anti-AML reagent in two different human 
AML mouse xenograft models. In solid tumour xenografts 
of U937, systemic administration of PEP005 inhibited 
tumour growth significantly. In an alternative AML 
model, GFP-NB4 cells were intravenously transplanted 
into NOD/SCID and NOD/SCID/β2mnull mice. Although 
PEP005 treatment did not significantly increase the 
survival of the diseased mice, it did have a marked effect 
on tumour burden, particularly reducing GFP-NB4 cell 
infiltration in lymph nodes. Bearing in mind that this 
type of xenograft model is so aggressive that the average 
survival time of mice was approximately 30-40 days, at 
the time of PEP005 treatment (day 14), the disease was 
already well-established. Future studies should include 
optimized dosing schedule to better understand the anti-
tumour effect.
Although PEP005 treatment led to apoptosis in 
the majority of patient samples tested, there were a 
small number that did not enter apoptosis in response 
to PEP005 treatment, even at the relatively high dose of 
100 nM. We were therefore interested in trying to define 
a molecular response phenotype that would predict poor 
prognosis and resistance to treatment if PEP005 goes to 
clinical trial. We have previously shown in leukaemic 
cell lines, that the anti-leukaemic effects of PEP005 were 
dependent on the expression and activation of PKC-δ, an 
isoform of PKC which has long been associated with a 
pro-apoptotic function [17;18]. Despite the association 
between PEP005 responsiveness and the expression 
and activation of PKC-δ in leukaemic cell lines, we 
found that both PEP005 responsive and non-responsive 
primary AML blasts expressed high levels of PKC-δ. In 
Figure 3: PEP005 treatment leads to the activation of PKC-δ in both responsive and non-responsive patient samples. 
Primary AML samples were grouped into non-responders (A), low-responders (B) or responders (C) based on their apoptotic response to 
PEP005 treatment. Apoptosis was measured using Annexin V/PI staining. D. Isolated AML blasts were cultured in medium alone (-) or 
10 nM PEP005 (+) for 30 minutes. SDS-PAGE and western blotting were then used to measure phospho-PKC-δ and PKC-δ expression, 
with β-actin used as a loading control. Samples that did not respond to PEP005 treatment in the apoptosis experiments were termed non-
responders (NR), and those that did respond were termed responders (R). E–G. Densitometric analysis was used to determine the ratio of 
total PKC-δ to β-actin (E) and phosphorylated to total PKC-d in both R (F) and NR (G) samples. * indicates p<0.05, ** indicates p<0.01.
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addition, we found activation of PKC-δ in both patient 
sample groups in response to treatment with PEP005. 
Primary AML blasts thus do not appear to down regulate 
PKC-d and this isoenzyme was phosphorylated at Thr505 
in response to PEP005. It is now well established that 
phosphorylation is essential for the regulation of PKC, 
enabling the enzymes to gain catalytic competence and 
correct intracellular localization [19]. However, in the 
case of PKC-δ, phosphorylation does not seem to be 
necessary to enable the enzyme to be a functional kinase. 
In particular, site directed mutagenesis studies have shown 
that phosphorylation at Thr505 is not essential for the 
activation of PKC-δ, unlike the corresponding threonine 
residues on PKC-α and PKC-βII [20]. Phosphorylation of 
PKC instead appears to be a priming event that locks PKC 
isoforms into a closed, stabilized, catalytically competent 
state. 
It is possible that the translocation pattern of PKC-δ 
in response to PEP005 treatment may differ between the 
responsive and resistant samples. It is well documented 
that PKC requires translocation for its activation [21]. 
We have previously shown in leukaemic cell lines, that 
PEP005 treatment leads to a translocation of PKC-δ to the 
nucleus, a pattern of translocation particularly associated 
with apoptosis [17;18;22], and this pattern of PKC-δ 
translocation in response to PEP005 has also been shown 
in CHO-K1 cells transfected with GFP-tagged PKC-δ 
[23]. Future studies should investigate whether PKC-d 
translocation differed between resistant and sensitive cells.
To further elucidate the mechanism of resistance 
to PEP005, we carried out whole genome expression 
microarray analysis. We found approximately 134 genes 
Figure 4: PEP005 treated non-responders show a distinct transcriptional profile. A. Significance analysis of microarrays 
(SAM) gene lists were used to perform a hierarchical clustering for both the samples and genes. The heat map scale represents the gene 
value relative to a standard reference sample expressed as the log2 ratio of reference/sample; therefore green represents higher and red 
lower relative expression for each sample. B-D. Five non-responder and 4 responder AML blast samples were treated with 100 nM PEP005 
and mRNA isolated after 6 hours and measured by quantitative PCR to confirm induction of Bcl-2A1 (B), PHLDA1 (C) and Mcl-1 (D). 
The horizontal bar shows the median value. * indicates p<0.05.
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that showed a significant difference in expression levels 
following PEP005 treatment in the resistant samples. PAM 
revealed that of these genes, some of the 25 most predictive 
were genes that encoded for proteins with known anti-
apoptotic function. These included Bcl-2A1, Mcl-1 and 
PHLDA1, the increased expression of which was confirmed 
using qPCR. Numerous studies have demonstrated 
overexpression of Bcl-2A1 in human leukaemia’s including 
Acute Lymphoblastic Leukaemia (ALL) [24;25] and AML 
[25;26]. In addition, Bcl-2A1 has already been suggested 
to be involved in promoting drug resistance in cancer cell 
lines. In particular, the over-expression of Bcl-2A1 has 
been shown to mediate the resistance to etoposide [27] and 
staurosporine [28]. Bcl-2A1 has also been shown to be up-
regulated in response to GM-CSF treatment in the AML 
cell line TF-1, conferring resistance to TNFα mediated 
apoptosis [29]. Moreover, the expression of Bcl-2A1 has 
been shown to correlate with resistance to chemotherapy 
in vivo, in Chronic Lymphocytic Leukaemia (CLL) [30]. 
Similarly, Mcl-1 has been shown to be expressed at high 
levels in the leukaemic stem cell fraction of AML cells 
when compared to normal haematopoietic stem cells [31] 
and Mcl-1 over-expression has been shown to have a role 
in resistance of leukaemic cells to Flt-3 inhibitors [32]. The 
increased expression of the genes in response to PEP005 
may explain why these particular samples are resistant to 
the ability of the compound to induce apoptosis as well as 
providing a simple way to test for potential responsiveness 
to the compound.
In summary, we have demonstrated that the 
novel plant derived compound PEP005 has potent anti-
leukaemic effects both in vitro and in vivo and have shown 
that certain non-responsive leukaemic cells are rendered 
resistant to apoptosis induction by up-regulating key 
anti-apoptotic genes. The latter may represent a useful 
diagnostic marker of responsiveness to PEP005 if the 
compound progresses to clinical trial.
Table 2: Predictive analysis of microarrays (PAM) was used to determine the change in expression of which 
genes best predicted whether a sample was a responder or a non-responder. 











FASLG 2.391 -1.588 0.604 -3.979 1.125 9.109 0.00027
PHLDA1 3.123 0.100 1.324 -3.023 1.582 7.885 0.00053
CTSL 2.410 2.106 1.800 -0.304 1.805 7.813 0.00055
H200019156 4.483 -0.350 1.541 -4.833 1.997 6.944 0.00095
SLC7A1 2.166 -0.594 0.811 -2.759 1.229 6.842 0.00102
IRF4 2.531 0.836 0.606 -1.695 1.439 6.732 0.00110
MCL1 2.013 -1.121 0.498 -3.135 1.212 6.680 0.00114
ITGA2 2.933 1.088 0.710 -1.845 1.599 6.679 0.00114
IL23A 2.486 -0.800 0.540 -3.285 1.247 6.532 0.00126
GLPK3_HUMAN 2.847 1.241 0.792 -1.606 1.446 6.351 0.00143
NP 2.377 -1.422 1.577 -3.799 1.509 5.772 0.00219
BCL2A1 2.942 -0.400 1.122 -3.343 1.838 5.761 0.00221
UPP1 2.318 -1.766 1.018 -4.083 1.634 5.648 0.00242
CDKN1A 2.425 -1.781 1.020 -4.206 1.845 5.550 0.00261
NP_116106.2 2.742 0.270 1.038 -2.472 1.872 5.391 0.00296
SLC7A11 2.662 -0.179 1.405 -2.842 0.905 5.335 0.00310
CD69 3.438 -1.561 0.292 -4.998 1.664 5.209 0.00344
Q9HBF5_HUMAN 2.713 0.460 1.339 -2.253 1.945 5.069 0.00387
RGS13 2.084 -0.803 0.551 -2.887 1.210 4.855 0.00465
DUSP5 2.587 -0.419 0.742 -3.006 1.671 4.828 0.00477
DUSP5 2.591 -0.241 0.143 -2.831 1.378 4.698 0.00535
H300014024 2.030 1.046 0.682 -0.984 1.033 4.697 0.00535
NLRP3 2.413 -2.175 1.438 -4.588 2.434 4.684 0.00541
INSIG1 2.556 0.561 0.815 -1.995 1.215 4.651 0.00558
NR4A1 2.546 -1.867 1.047 -4.414 1.429 4.589 0.00590
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MATERIALS AND METHODS
Reagents were purchased from Sigma-Aldrich 
unless otherwise stated.
PEP005 preparation
PEP005 was supplied as a 98.5% pure preparation 
by Peplin Ltd, (Brisbane, Australia) as a dry pellet and 
was made up to a stock of 10 mg/ml in dimethyl sulfoxide 
(DMSO). Stocks were diluted in RPMI-1640 media 
supplemented with 10% heat inactivated (HI) fetal calf 
serum (FCS, Sera Laboratories International) (vol/vol), 
streptomycin (100 ug/ml), penicillin (100 U/ml) and 2 mM 
L-glutamine. 
Purification of Peripheral Blood Mononuclear 
Cells (PBMCs)
The study was approved by the local Research Ethics 
Committee and all samples were collected after written 
informed consent. Leukaemic PBMCs were isolated from 
the peripheral blood of AML patients with at least 80% 
leukaemic blasts amongst leucocytes using Ficoll (GE 
Healthcare) density centrifugation. The percentage of 
leukaemic blasts in isolated samples exceeded 95% for all 
patients as judged by light microscopy. 
Culture and treatment of isolated cells 
To examine the effects of PEP005 on leukaemic cell 
survival and proliferation, cells were treated with a vehicle 
control or PEP005 (2 nM-20 μM). 
Detection of apoptosis
Cells were stained with Annexin-V and Propidium 
Iodide using a commercially available apoptosis assay 
kit according to the manufacturer’s instructions (Apotest, 
Nexins Research). 10,000 events were analysed on a 
FACSCalibur cytometer (Becton Dickinson) and data 
analysed using WinMDI software.
Measurement of proliferation using 3H-thymidine 
incorporation
AML blasts were resuspended at a concentration of 
2 x 106/ml in stem span medium (Stem Cell Technologies) 
supplemented with 20 ng/ml of recombinant human 
Flt-3 ligand, stem cell factor (SCF) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (all 
from Peprotech Ltd), and 100 μg/ml gentamicin. 2 x 105 
cells were treated with either medium alone or PEP005 
(1nM-1μM) and cultured at 37ºC/5% CO2 for 7 days. Post 
culture, 3H-thymidine (Amersham Biosciences) was added 
in 20 μl of 0.9% NaCl solution and 18 hours later, cells 
harvested using a Skatron Micro96 harvester onto filter 
mats (Cox Scientific). Filter mats were left to air dry and 
3H-thymidine incorporation was measured using a liquid 
scintillation counter. Results are expressed as counts per 
minute (CPM).
Animals
Male and female NOD-SCID mice (Table 2) and 
NOD/LtSz-Prkdcscid/B2mnull mice (Figure 3, abbreviated as 
NOD/SCID/β2mnull), originally obtained from Dr. Leonard 
Schultz, (Jackson Laboratories, Bar Harbor, Maine, USA) 
were used for the GFP-NB4 leukaemia model. Nude 
mice were used for the U937 subcutaneous leukaemia 
model. All experiments were approved by The Norwegian 
or German Animal Research Authority and conducted 
according to The European Convention for the Protection 
of Vertebrates Used for Scientific Purposes.
U937 subcutaneous leukaemia model
6-8 week old nude mice were subcutaneously 
injected with 5 x 106 U937 cells. 14 days post inoculation 
(normalized as day 0), mice (8 mice per group) received tail 
vein injections of different doses (40, 60 and 80mg/kg/d) 
of PEP005-PEG400 (provided by Peplin Ltd.) or vehicle 
control 3 times a week for two weeks. Tumor volume 
was determined by a two dimensional measurement 
with calliper on the day of randomization and then twice 
weekly. The relative volume of an individual tumor on day 
X (RTVx) is calculated by dividing the absolute volume 
[mm3] of the tumor on day X (Tx) by the absolute volume 
of the same tumor on the day of randomization, multiplied 
by 100 (RTVx=Tx/T0*100). Mice were sacrificed when 
individual tumor volume exceeded 2000mm3, body weight 
loss exceeded 30% and/or when a severe impairment of 
general condition was observed.
GFP-NB4 leukaemia model
6-8 week old NOD/SCID and NOD/SCID/β2mnull 
mice were irradiated from a photon radiation source (BCC 
Dynaray CH4, 4 megavolt photon irradiation source, with 
a sub-lethal dose of 2.5 Gy (60 cGy/min)) 24 hours prior 
to transplantation. NB4-GFP cells (107) were injected via 
the dorsal tail vein. 2 weeks after GFP-NB4 inoculation, 
mice (6 mice per group) received tail vein injections of 
50 µg/kg PEP005-PEG400 or vehicle control once daily 
for 5 consecutive days. Recipient mice were monitored 
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by weighing every second day and imaging every 3 days, 
and sacrificed following institutional guidelines when 
moribund, as defined by weight loss, lethargy and/or 
paralysis. 
In order to directly compare leukaemic infiltration 
and tumour burden between control and treated mice, 
different tissues were collected after mice were sacrificed. 
Tissues were homogenised and filtered through a 40 μm 
cell strainer (BD Biosciences). Red blood cells were lysed 
using lysing solution (150mM NH4Cl, 10mM KHCO3 and 
20mM EDTA). Samples with acquisitions of 10,000 cells 
were subsequently run on a FACS Calibur flow cytometer 
(BD Biosciences) and gated against GFP+ cells. 
Time-Domain GFP Fluorescence Imaging
Anaesthetised mice (1% isofluorane), were 
depilated and moved to the heated translational stage of 
an eXpore Optix™ (ART/GE Healthcare) configured 
for GFP imaging experiments as previously described 
[14]. The integration time and laser power for animals 
was optimised per animal prior to scanning, with a raster 
scan interval of 1 mm. Whole body images of leukaemic 
mice were taken prior to leukaemic inoculation and 
used as representative background auto fluorescence, 
per animal. GFP fluorescence images were generated 
using Optiview™ software (ART/GE Healthcare) gating 
for fluorescence lifetime of GFP at 2.7 ns as previously 
described [14].
SDS-PAGE and western blotting
Expression and activation of PKC-δ were 
determined by western blotting of cell extracts using 
antibodies to total PKC-δ (Santa Cruz) as well as 
PKC-δ phosphorylated at threonine 505 (Cell Signalling 
Technologies). Total cell lysates were obtained by 
resuspending the cells in SDS sample buffer (0.5 M 
Tris pH 6.8, 10% β-mercaptoethanol, 10% SDS, 20% 
Glycerol, 0.1% bromophenol blue) and heated for 10 
minutes at 100°C. Lysates were loaded onto a 12% 
SDS-polyacrylamide gel (SDS-PAGE). Proteins were 
subsequently transferred to 0.45 micron polyvinylidene 
difluoride membrane (Flowgen). Blots were probed 
with the relevant primary antibodies and secondary 
antibodies conjugated to horse radish peroxidase 
(Dako Ltd) after which, proteins were visualised using 
enhanced chemiluminescence (Amersham Pharmacia) 
and autoradiography against X-ray film (Kodak). Equal 
loading of proteins was assessed by probing blots for 
β-actin.
Gene expression microarray analysis
RNA was extracted using the Qiagen RNAeasy 
kit according to manufacturer’s instructions (Qiagen). 
Reverse transcription of the RNA was achieved by adding 
5μg of RNA to 1μl oligo(dT)12-18 primer (Invitrogen). This 
was then heated to 650C for 10 minutes, and cooled on ice 
before addition of 8μl of 1st strand buffer, 4μl 0.1M DTT 
(Invitrogen), and 2μl Superscript II 200U/μl (Invitrogen) 
as well as 8μl 10mM dNTPs (Invitrogen). The reaction 
was then kept at 420C for 2 hours. cDNA was extracted 
using a PCR Purification Kit (Machery-Nagel) as per 
the kit instructions. Cy3-dCTP and Cy5-dCTP labelling 
was performed using 500 ng of sample cDNA and the 
labelled cDNA was purified using a PCR Purification Kit. 
Labelled cDNA was then added to a microarray consisting 
of the Human Genome Array Ready Oligo Set version 
4.0 (Operon). Data were acquired using a ScanArray Gx 
Plus (PerkinElmer). All samples were run in parallel to a 
Universal Human Reference RNA sample. Hybridizations 
were carried out within Corning Hybridization Chambers 
overnight, using Lifter Slips (VWR International). Data 
normalization was performed using the Gene Expression 
Pattern Analysis Suite (www.gepas.org) [15]. Using log-
normalized ratios, the TIGR Multiexperiment Viewer 
version 4.0 was used to perform significance analysis 
of microarrays. Hierarchical clustering and principal 
component analysis were performed on the resultant gene 
list. 
mRNA quantification by quantitative real time 
PCR (qPCR)
B-cell lymphoma 2-related protein A1 (Bcl-2A1), 
myeloid cell leukaemia sequence 1 (Mcl-1), Pleckstrin 
homology-like domain family A member 1 (PHLDA1) 
and L-27 mRNA were analysed by qPCR using Taqman 
PCR probes. Bcl-2A1, Mcl-1 and PHLDA-1 FAM-
labelled primers, and L-27 VIC-labelled primers were 
synthesised by Eurogentec. Samples were amplified using 
the Stratagene MX3000P qPCR machine and analysed 
using MXPro software (Agilent Technologies). 
Statistical analysis
Non-parametric statistical analysis was used that 
included the Mann Whitney U test, the Wilcoxon Signed 
Rank Test and the Kruskal-Wallis test. When analysing 
data from a normal (Gausian) distribution, parametric tests 
such as t-test, paired t-test and one way ANOVA were 
used. All statistical analysis was carried out using version 
4 of the GraphPad Prism software (GraphPad software 
limited). Results were considered significant at p<0.05.
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